Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/22960Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Rizos, C. V. | en |
| dc.contributor.author | Liberopoulos, E. N. | en |
| dc.contributor.author | Tellis, C. C. | en |
| dc.contributor.author | Florentin, M. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.contributor.author | Tselepis, A. D. | en |
| dc.date.accessioned | 2015-11-24T19:29:15Z | - |
| dc.date.available | 2015-11-24T19:29:15Z | - |
| dc.identifier.issn | 1557-8518 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22960 | - |
| dc.rights | Default Licence | - |
| dc.subject | 1-Alkyl-2-acetylglycerophosphocholine Esterase/*blood/drug effects/metabolism | en |
| dc.subject | Aged | en |
| dc.subject | Angiotensin II Type 1 Receptor Blockers/*administration & dosage/pharmacology | en |
| dc.subject | Benzimidazoles/administration & dosage/pharmacology | en |
| dc.subject | Benzoates/administration & dosage/pharmacology | en |
| dc.subject | Drug Combinations | en |
| dc.subject | Enzyme Activation/drug effects | en |
| dc.subject | Female | en |
| dc.subject | Fluorobenzenes/*administration & dosage/pharmacology | en |
| dc.subject | Humans | en |
| dc.subject | Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & | en |
| dc.subject | dosage/pharmacology | en |
| dc.subject | Lipoproteins, LDL/*blood/drug effects/metabolism | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | PPAR gamma/*agonists/metabolism | en |
| dc.subject | Pyrimidines/*administration & dosage/pharmacology | en |
| dc.subject | Sulfonamides/*administration & dosage/pharmacology | en |
| dc.title | Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-gamma activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1089/met.2010.0120 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/21352079 | - |
| heal.identifier.secondary | http://online.liebertpub.com/doi/pdfplus/10.1089/met.2010.0120 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2011 | - |
| heal.abstract | BACKGROUND: Rosuvastatin reduces low-density lipoprotein cholesterol (LDL-C) and plasma lipoprotein-associated phospholipase A (Lp-PLA) Some sartans partially activate peroxisome proliferator-activated receptor-gamma (PPARgamma), possibly having a favorable effect on metabolic parameters. Telmisartan is the most potent partial PPARgamma activator, followed by irbesartan, whereas olmesartan does not hold such capacity. In an open-label randomized study, we assessed the effects of combining sartans of different PPARgamma- activating capacity with rosuvastatin on LDL subfractions and plasma Lp-PLA in patients with mixed dyslipidemia, hypertension, and prediabetes. METHODS: Following dietary intervention, patients were allocated randomly to rosuvastatin (10 mg/day) plus telmisartan 80 mg/day (RT group, n = 52) or irbesartan 300 mg/day (RI group, n = 48) or olmesartan 20 mg/day (RO group, n = 51). After 6 months of treatment, changes in LDL subfraction cholesterol and plasma Lp-PLA(2) activity and mass were evaluated blindly. RESULTS: A total of 151 patients (73 male; mean age 60 years) were included. Large LDL-C decreased in the RT (-36%), RI (-39%), and RO (-41%) groups (P < 0.001 for all vs. baseline). Small dense LDL-C decreased in the RT (-67%), RI (-58%), and RO (-61%) groups (P < 0.001 for all vs. baseline). All regimens increased LDL particle size versus baseline (RT + 1.4%, P = 0.002; RI + 1.0%, P = 0.04; and RO + 1.4%, P = 0.001). No difference for the change of LDL subfractions and LDL size was noticed among groups. Plasma Lp-PLA activity decreased equally in all groups (RT -38%, RI -38%, RO -43%) (P < 0.001 for all vs. baseline). Plasma Lp-PLA mass decreased similarly in all groups versus baseline (RT -28%, P = 0.001; RI -32%, P = 0.01; and RO -27%, P = 0.001). No difference for the change of Lp-PLA mass or activity was noticed among groups. CONCLUSIONS: The combination of rosuvastatin with sartans of different PPARgamma-activating capacity did not differentiate alterations of LDL subfraction cholesterol and plasma Lp-PLA(2) activity and mass. | en |
| heal.journalName | Metab Syndr Relat Disord | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Rizos-2011-Combining rosuvastat.pdf | 181.95 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
